Citation: Felipe Bisbal MD, Lluís Mont MD PhD
Since Haissaguerre et al first described the pathogenic role of pulmonary vein firing as a crucial mechanism triggering atrial fibrillation, catheter ablation has been recommended as a curative treatment. Several trials have demonstrated that ablation is an effective treatment in most patients with paroxysmal atrial fibrillation and low-grade remodelled atria. In patients with persistent AF, there is substantially less evidence, mostly based on non-randomized studies, supporting this recommendation. The available scientific evidence as well as the current approaches to treating persistent AF patients are discussed in this article. Further, we describe the main findings of the SARA trial and put them into perspective.
Since Haissaguerre et al first described the pathogenic role of pulmonary vein firing as a crucial mechanism triggering atrial fibrillation, catheter ablation has been recommended as a curative treatment. Several trials have demonstrated that ablation is an effective treatment in most patients with paroxysmal atrial fibrillation and low-grade remodelled atria. In patients with persistent AF, there is substantially less evidence, mostly based on non-randomized studies, supporting this recommendation. The available scientific evidence as well as the current approaches to treating persistent AF patients are discussed in this article. Further, we describe the main findings of the SARA trial and put them into perspective.
No comments:
Post a Comment